journal article·2019-09Open access

Benchmarking to the Gold Standard: Hyaluronan‐Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture

Alexander E. G. Baker, Laura C. Bahlmann, Roger Y. Tam, Jeffrey C. Liu, Ahil N. Ganesh, Nikolaos Mitrousis, Richard Marcellus, Melanie Spears, John M. S. Bartlett, David W. Cescon, Gary D. Bader, Molly S. Shoichet

Advanced Materials· Volume 31· Issue 36

Abstract

Abstract Many 3D in vitro models induce breast cancer spheroid formation; however, this alone does not recapitulate the complex in vivo phenotype. To effectively screen therapeutics, it is urgently needed to validate in vitro cancer spheroid models against the gold standard of xenografts. A new oxime‐crosslinked hyaluronan (HA) hydrogel is designed, manipulating gelation rate and mechanical properties to grow breast cancer spheroids in 3D. This HA‐oxime breast cancer model maintains the gene expression profile most similar to that of tumor xenografts based on a pan‐cancer gene expression profile (comprising 730 genes) of three different human breast cancer subtypes compared to Matrigel or conventional 2D culture. Differences in gene expression between breast cancer cultures in HA‐oxime versus Matrigel or 2D are confirmed for 12 canonical pathways by gene set variation analysis. Importantly, drug response is dependent on the culture method. Breast cancer cells respond better to the Rac inhibitor (EHT‐1864) and the PI3K inhibitor (AZD6482) when cultured in HA‐oxime versus Matrigel. This study demonstrates the superiority of an HA‐based hydrogel as a platform for in vitro breast cancer culture of both primary, patient‐derived cells and cell lines, and provides a hydrogel culture model that closely matches that in vivo.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Donnelly Centre University of Toronto Toronto 160 College St Ontario M5S 3E1 Canada

Department of Chemical Engineering and Applied Chemistry University of Toronto 200 College Street Toronto Ontario M5S 3E5 Canada

Institute of Biomaterials and Biomedical Engineering 164 College Street Toronto Ontario M5S 3G9 Canada

Ontario Institute for Cancer Research MaRS Centre 661 University Avenue Toronto Ontario M5G 0A3 Canada

Department of Laboratory Medicine and Pathology University of Toronto 1 King's College Circle Toronto Ontario M5S 1A8 Canada

Princess Margaret Cancer Centre University Health Network 610 University Ave. Toronto Ontario M5G 2C1 Canada

Department of Chemistry University of Toronto 80 St. George Street Toronto Ontario M5S 3H6 Canada

Funding

Natural Sciences and Engineering Research Council of Canada · Canadian Institutes of Health Research

References (54)

Show source-provided references
1. 10.3762/bjoc.12.26710.3762/bjoc.12.267 ↗
2. 10.1016/j.ymeth.2017.08.01010.1016/j.ymeth.2017.08.010 ↗
3. Li Y. · Sci. Adv. · 2018 · 4 · eaas899
4. 10.18632/oncotarget.2247510.18632/oncotarget.22475 ↗
5. 10.1136/jclinpath-2015-20306610.1136/jclinpath-2015-203066 ↗
6. 10.1016/j.cell.2015.08.06810.1016/j.cell.2015.08.068 ↗
7. Ivascu A. · Int. J. Oncol. · 2007 · 31 · 1403
8. 10.3892/or.2015.376710.3892/or.2015.3767 ↗
9. 10.18632/oncotarget.1130710.18632/oncotarget.11307 ↗
10. Madoux F. · SLAS Discovery · 2017 · 22 · 51610.1177/2472555216686308 ↗
11. 10.1016/j.neo.2017.06.00410.1016/j.neo.2017.06.004 ↗
12. 10.15252/msb.2014564410.15252/msb.20145644 ↗
13. 10.1021/acsbiomaterials.7b0006910.1021/acsbiomaterials.7b00069 ↗
14. 10.1039/C0IB00087F10.1039/C0IB00087F ↗
15. 10.1186/s12885-017-3953-610.1186/s12885-017-3953-6 ↗
16. 10.1016/j.addr.2014.01.00110.1016/j.addr.2014.01.001 ↗
17. 10.1002/pmic.20090075810.1002/pmic.200900758 ↗
18. 10.1016/j.dental.2014.08.36910.1016/j.dental.2014.08.369 ↗
19. 10.1016/S0002-9440(10)64757-810.1016/S0002-9440(10)64757-8 ↗
20. 10.1038/npjbcancer.2015.1710.1038/npjbcancer.2015.17 ↗
21. 10.1002/adfm.20160560910.1002/adfm.201605609 ↗
22. 10.1021/cb500672810.1021/cb5006728 ↗
23. 10.1021/jacs.7b0051310.1021/jacs.7b00513 ↗
24. 10.1016/j.biomaterials.2016.02.02310.1016/j.biomaterials.2016.02.023 ↗
25. 10.1002/anie.20080265110.1002/anie.200802651 ↗
26. 10.1021/acs.biomac.6b0135510.1021/acs.biomac.6b01355 ↗
27. 10.1021/acs.biomac.7b0142210.1021/acs.biomac.7b01422 ↗
28. 10.18632/oncotarget.417310.18632/oncotarget.4173 ↗
29. 10.1039/C5AN01997D10.1039/C5AN01997D ↗
30. 10.1016/j.ccr.2005.08.01010.1016/j.ccr.2005.08.010 ↗
31. 10.1016/j.cell.2009.10.02710.1016/j.cell.2009.10.027 ↗
32. 10.1016/j.jmbbm.2015.12.02810.1016/j.jmbbm.2015.12.028 ↗
33. 10.18632/oncotarget.1263010.18632/oncotarget.12630 ↗
34. 10.1002/term.37810.1002/term.378 ↗
35. 10.1002/adhm.20170025410.1002/adhm.201700254 ↗
36. 10.1089/ten.tea.2009.038110.1089/ten.tea.2009.0381 ↗
37. 10.1073/pnas.152125511310.1073/pnas.1521255113 ↗
38. 10.1016/j.ijbiomac.2008.08.00910.1016/j.ijbiomac.2008.08.009 ↗
39. 10.1002/jbm.a.3063810.1002/jbm.a.30638 ↗
40. 10.1016/j.cell.2008.06.00610.1016/j.cell.2008.06.006 ↗
41. 10.1158/0008-5472.CAN-09-315510.1158/0008-5472.CAN-09-3155 ↗
42. 10.1186/1471-2407-9-9410.1186/1471-2407-9-94 ↗
43. 10.1093/jb/mvt08510.1093/jb/mvt085 ↗
44. 10.1002/ijc.2770710.1002/ijc.27707 ↗
45. 10.1038/onc.2015.48910.1038/onc.2015.489 ↗
46. 10.1007/s10549-009-0508-910.1007/s10549-009-0508-9 ↗
47. 10.1080/14728222.2017.138108710.1080/14728222.2017.1381087 ↗
48. 10.18632/oncotarget.1549410.18632/oncotarget.15494 ↗
49. 10.3389/fonc.2016.0026210.3389/fonc.2016.00262 ↗
50. 10.1016/j.ymben.2017.01.01010.1016/j.ymben.2017.01.010 ↗
51. 10.3390/ijms1812254310.3390/ijms18122543 ↗
52. 10.1200/JCO.2018.36.15_suppl.e2421610.1200/JCO.2018.36.15_suppl.e24216 ↗
53. 10.1158/1535-7163.MCT-06-051410.1158/1535-7163.MCT-06-0514 ↗
54. 10.18632/oncotarget.239110.18632/oncotarget.2391 ↗